EPO and Huntington disease: A few reports investigated only erythrocyte complement receptor type 1 (E-CR1) among HD patients as follows: recombinant human erythropoietin improved anemia and increased the level of E-CR1 [24], and a low level of E-CR1 was associated with poor prognosis in HD patients [25].